# InMed’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

* Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces
* InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need
* Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model

 Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces. InMed Pharmaceuticals (NASDAQ: INM), a clinical stage company developing a pipeline of pharmaceutical drug candidates to treat several diseases with a high unmet medical need, is at the forefront of developing innovative treatments for this debilitating condition, with their flagship product INM-089 showing great promise.

 AMD is the leading cause of vision loss among people aged 50 and older. It comes in two forms: dry AMD, which is more common and less severe, and wet AMD, which is rarer but more severe. The exact cause of AMD is not fully understood, but it is believed to involve a combination of…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

 About CannabisNewsWire

 CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.CannabisNewsWire.com

 Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

 CannabisNewsWireDenver, COwww.CannabisNewsWire.com303.498.7722 OfficeEditor@CannabisNewsWire.com

 CannabisNewsWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ibn-prem/inmeds-nasdaq-inm-inm-089-a-promising-treatment-for-age-related-macular-degeneration/)
                    

[Newsramp.com TLDR](None) 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1f2fn0j/inmed_pharmaceuticals_advances_promising/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/248/27/dashVOT0.webp)